정맥주사액 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 판매 채널별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Intravenous Solutions Market Summary

The global intravenous solutions market size was valued at USD 18.1 billion in 2025 and is projected to grow from USD 19.3 billion in 2026 to USD 28.7 billion by 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for thelargest revenue share of 41.8% in 2025. This growth is attributed to the increasing prevalence of diseases, such as neurological diseases, gastrointestinal diseases, and cancer. Intravenous (IV) solutions provide essential nutrients and are a main source of energy.

Global Intravenous Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Intravenous solutions market report based on product type, sales channel, end use, and region.

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Crystalloid Solutions
  • Normal Saline (0.9% Sodium Chloride)
  • Half Normal Saline (0.45% Sodium Chloride)
  • Dextrose Solutions
  • Dextrose 5% Injection
  • Dextrose 10% Injection
  • Dextrose 50% Injection
  • Dextrose-Saline Solutions
  • Dextrose 5% and Sodium Chloride 0.9% Infusion
  • Dextrose 4.3% and Sodium Chloride 0.18% Infusion
  • Ringer's Solution
  • Lactated Ringer's Solution
  • Balanced Crystalloid Solutions
  • Plasma-Lyte
  • Normosol
  • Hypertonic Saline (3%, 5%, etc.)
  • Other Crystalloid Solutions
• Colloid Solutions
• Parenteral Nutrition (PN) Solutions
  • Total Parenteral Nutrition (TPN)
  • Standard TPN
  • Customized TPN
  • Ready-to-use Multi-Chamber Bags
  • Peripheral Parenteral Nutrition (PPN)
  • Ready-to-use PPN
  • Customized PPN
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online
• Retail
• Institutional
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Home
• Hospitals
• Infusion Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Sales Channel
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Number of Surgical Procedures
    • 3.2.1.2. Growing Number of Premature Births
    • 3.2.1.3. Increasing Incidence of Cancer
    • 3.2.1.4. Increasing Risk of Malnutrition
    • 3.2.1.5. Growing Geriatric Population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product Shortages and Supply Chain Disruptions
    • 3.2.2.2. Increased Use of Enteral Nutrition
    • 3.2.2.3. High Risk of Infections
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Regulatory Framework
    • 3.2.5.1. Standards and Compliances
      • 3.2.5.1.1. North America
      • 3.2.5.1.2. Europe
      • 3.2.5.1.3. Asia Pacific
      • 3.2.5.1.4. Latin America
      • 3.2.5.1.5. MEA
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Intravenous Solutions Market: Product Type Estimates & Trend Analysis

• 4.1. Product Type Segment Dashboard
• 4.2. Product Type Market Share Movement Analysis, 2025 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2021 to 2033 (Revenue USD Million)
• 4.4. Crystalloid Solutions
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.2. Normal Saline (0.9% Sodium Chloride)
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.3. Half Normal Saline (0.45% Sodium Chloride)
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.4. Dextrose Solutions
    • 4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.4.2. Dextrose 5% Injection
      • 4.4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.4.3. Dextrose 10% Injection
      • 4.4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.4.4. Dextrose 50% Injection
      • 4.4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.5. Dextrose-Saline Solutions
    • 4.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.5.2. Dextrose 5% and Sodium Chloride 0.9% Infusion
      • 4.4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.5.3. Dextrose 4.3% and Sodium Chloride 0.18% Infusion
      • 4.4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.6. Ringer's Solution
    • 4.4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.7. Lactated Ringer's Solution
    • 4.4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.8. Balanced Crystalloid Solutions
    • 4.4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.8.2. Plasma-Lyte
      • 4.4.8.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.4.8.3. Normosol
      • 4.4.8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.9. Hypertonic Saline (3%, 5%, etc.)
    • 4.4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.4.10. Other Crystalloid Solutions
    • 4.4.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 4.5. Colloid Solutions
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 4.6. Parenteral Nutrition (PN) Solutions
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.6.2. Total Parenteral Nutrition (TPN)
    • 4.6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.6.2.2. Standard TPN
      • 4.6.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.6.2.3. Customized TPN
      • 4.6.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.6.2.4. Ready-to-use Multi-Chamber Bags
      • 4.6.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 4.6.3. Peripheral Parenteral Nutrition (PPN)
    • 4.6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.6.3.2. Ready-to-use PPN
      • 4.6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
    • 4.6.3.3. Customized PPN
      • 4.6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 5. Intravenous Solutions Market: Sales Channel Estimates & Trend Analysis

• 5.1. Sales Channel Segment Dashboard
• 5.2. Sales Channel Market Share Movement Analysis, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Sales, 2021 to 2033 (Revenue USD Million)
• 5.4. Online
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.5. Retail
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.6. Institutional
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 6. Intravenous Solutions Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. End Use Market Share Movement Analysis, 2025 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (Revenue USD Million)
• 6.4. Home
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 6.5. Hospitals
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 6.6. Infusion Centers
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 7. Intravenous Solutions Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market: Key Takeaways
• 7.3. North America
  • 7.3.1. North America Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamic
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive insights
    • 7.3.2.4. U.S. Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive insights
    • 7.3.3.4. Canada Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Competitive insights
    • 7.3.4.4. Mexico Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.4. Europe
  • 7.4.1. Europe Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. Germany Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. UK Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. France Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamic
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive insights
    • 7.4.5.4. Italy Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamic
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive insights
    • 7.4.6.4. Spain Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamic
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive insights
    • 7.4.7.4. Denmark Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamic
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive insights
    • 7.4.8.4. Sweden Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamic
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive insights
    • 7.4.9.4. Norway Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. Japan Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. China Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. India Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. South Korea Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Australia Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Thailand Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Intravenous Solutions Market Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Brazil Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. Argentina Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.7. MEA
  • 7.7.1. MEA Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. South Africa Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Saudi Arabia Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamic
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive insights
    • 7.7.4.4. UAE Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamic
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive insights
    • 7.7.5.4. Kuwait Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis/Company Market Share Analysis, (2025)
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Fresenius Kabi AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. B. Braun SE
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Baxter
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Otsuka Pharmaceutical Co., Ltd.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Pfizer, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. JW Life Science
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Vifor Pharma
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. ICU Medical, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Grifols, S.A.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Kelun
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. SJZ No.4 Pharmaceutical
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. AdvaCare Pharma
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product benchmarking
    • 8.5.12.4. Strategic initiatives